 The presentation, entitled: Results from a Phase 2, Open-Label, Multicenter, 2x2 Cross-over Trial to Assess the Safety and Efficacy of MS1819 in Patients with Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis, will be delivered by Dr. Michael Konstan, Vice Dean for Translational Research and Professor of Pediatrics at Case Western Reserve University in Cleveland, Ohio. Dr. Konstan will discuss the data from the Companys Phase II study of MS1819 in patients with cystic fibrosis, which demonstrated safety, a coefficient of fat absorption CFA which was similar to the value at the same dose in a prior study in chronic pancreatitis, and positive unexpected findings on the coefficient of nitrogen absorption CNA. 